Phenotypical and molecular characteristics of myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors and precursors at different stages of differentiation into granulocytes, macrophages, and dendritic cells. In healthy individuals, immature myeloid cells generated in bone marrow quickly differentiate into mature granulocytes, macrophages, or dendritic cells. Under pathological conditions such as cancer, infectious diseases, sepsis, trauma, bone marrow transplantation, or autoimmune disorders, a blockade in their differentiation into mature myeloid cells results in an expansion of this population [1] . Human MDSCs are identified as HLA-DR [4] . Human MDSCs commonly express Siglec-3/CD33 and lack lineage markers and HLA-DR, but heterogeneous expression of CD14 and CD15 suggests the presence of multiple subsets. Several other surface molecules have been used to identify additional subsets of MDSCs in cancer, including CD80, also known as B7.1 [5] , CD115 (the macrophage colony-stimulating factor receptor), and CD124 (the IL-4 receptor α-chain) [6, 7] . Although these proteins are expressed by MDSCs, they do not define a specific MDSC population with distinct suppressive functions. Human MDSCs do not express a marker homologous to mouse Gr-1.
In humans, identification of G-and M-MDSC subsets is difficult, they have been described by the combination of several myeloid markers that, in some instances, overlap partially or completely. Additionally, a more immature subset of human MDSCs characterised by the absence of staining for the lineage cocktail (CD3   -, CD14   -, CD15   -, CD19   -, CD56   -) , HLA-DR − , and expression of the common myeloid markers CD33 and CD11b has been identified as an "early stage" e-MDSC, defined. Using a multi-colour staining protocol and taking into account all the reported myeloid subsets endowed with a suppressive activity, a recent study discriminated six human MDSC phenotypes: MDSC1 (CD14 
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−/low for polymononuclear PMN-MDSCs, present in the mononuclear fraction [11] . According to the recommendations the current nomenclature of polymononuclear PMN-MDSCs, present in the mononuclear fraction, replaced former granulocytic G-MDSCs. Growing evidence shows that the phenotype and mechanisms of action of MDSCs are tumour-dependent; therefore, it is important to determine the presence of all MDSC subsets in each cancer patient [12] .
In mice, MDSCs are defined as CD11b 
CD49d
+ MDSCs [14] [15] [16] . Gr-1 antigen is a cell surface protein that belongs to the Ly-6 family of proteins. In rats MDSCs could be identified as CD11b + Gr-1 + cells (Fig. 2 ). MDSCs are of great interest because they have the capacity to suppress the cytotoxic activities of natural killer (NK) and NKT cells, and the adaptive immune response mediated by CD4 + and CD8 + T cells, and they induce apoptosis of T-cell subsets [17] . Multiple mechanisms responsible for MDSC-mediated T-cell suppression have been described. The two MDSC subsets inhibit immune responses through different mechanisms: PNM-MDSCs suppress antigen (Ag)-specific CD8 + T cells mainly by producing reactive oxygen species (ROS), while M-MDSCs function primarily by expressing nitric oxide synthase 2 (NOS2) and arginase 1 (ARG1), and by generating reactive nitrogen species [18] . ARG1 and NOS2 metabolise L-arginine and block translation of the T cell CD3 zeta chain, inhibit T-cell proliferation, and promote T-cell apoptosis. Moreover, MDSCs secrete immunosuppressive cytokines and induce regulatory T-cell progression. The proportions of PMN-MDSCs and M-MDSCs are variable in different tumour models. While the majority of MDSCs in peripheral lymphoid organs are PMN-MDSCs, the ratio between PMN-MDSCs and M-MDSCs is much lower at tumour sites. It has been proposed that chemokines produced by tumour cells could induce a preferential migration of M-MDSCs to the tumour site. Alternatively, special features of the tumour microenvironment such as hypoxia, low pH, and metabolic products might not support PMN-MDSC survival [18] .
Normal bone marrow contains 20-30% of cells with this phenotype, but these cells constitute only a small proportion (2-4%) of spleen cells and are absent from the lymph nodes in mice. In healthy individuals, immature myeloid cells with the described above phenotype comprise ∼0.5% of peripheral blood mononuclear cells [3] . Granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and macrophage colony stimulating factor (M-CSF) are haematopoietic growth factors responsible for the recruitment, proliferation, and maturation of myeloid cells [19] . One of the main concepts of MSDC generation, the emergency myelopoiesis states that an expansion signal 1, mediated mainly by STAT3 (induced by, e.g., GM-CSF, G-CSF, and IL-6), mobilises the immature myeloid cells from the bone marrow. An activation signal 2, mediated mainly by the transcription factor NFκB (induced by pro-inflammatory stimuli, e.g. TLR signalling and cytokines), follows [20] . The concept of block in differentiation states that immature myeloid cells are arrested in their immature phase by inflammatory mediators such as S100A8, S100A9, VEGF, IL-10, and COX-2/ prostaglandin PGE2 [21, 22] . The classical definition of MDSCs as immature myeloid cells blocked from terminal differentiation has been challenged by recent studies suggesting that M-MDSCs and PMN-MDSCs may represent monocytes and granulocytes that have acquired immunosuppressive properties [10] . Both emergency myelopoiesis and block in differentiation are linked to an abnormal and persistent activation of STAT3. It is believed that activation of STAT3 in myeloid progenitor cells leads to the induction of S100A8 and S100A9 expression, which subsequently acts in an autocrine manner to arrest the cells in their immature phase [23] . All MDSCs originate from common myeloid progenitors, and their development is probably governed by the same growth factors that control normal myelopoiesis, e.g. GM-CSF, G-CSF, and M-CSF. MDSC percentages increase under pathological conditions, as a result of signals released by tumour cells or chronic inflammation [24] . Emerging evidence suggests that M-MDSCs are generated by reprogramming of monocytes into M-MDSCs, whereas PMN-MDSCs might be generated from neutrophils through the activation of immature or mature granulocytes and represent different stages of activation [10] .
The frequency of MDSCs positively correlates with clinical stage and tumour burden in patients with breast [25] , gastric [26] , and colorectal cancers [27] . Increased levels of CD14 + HLA-DR -/low MDSCs were correlated with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients [28] .
The analysis of ten different experimental tumour models revealed that the expansion of the PMN-MDSC population was much greater than that of the monocytic subset, and the two subpopulations used different mechanisms to suppress T-cell function. The ability to differentiate into mature DCs and macrophages in vitro has been shown to be restricted to monocytic M-MDSCs [14] . Several studies have shown that bone marrow precursor cells treated with G-CSF or GM-CSF acquire a surface phenotype similar to MDSCs found in blood of cancer patients [29] [30] [31] .
Accumulation and functions of myeloid cells in gliomas
Gliomas are tumours of the central nervous system (CNS), originating from transformed neural stem or progenitor glial cells [32] . The World Health Organisation (WHO), based on histopathological characteristics, divided gliomas into groups: low-grade gliomas (grades I and II) are benign, well-differentiated, slow-growing tumours; whereas high-grade gliomas (grades III and IV) are poorly differentiated or anaplastic, rapidly proliferating, and strongly infiltrate brain parenchyma. The most frequent and malignant primary brain tumour is glioblastoma (GBM, grade IV). Histological classification is currently assisted by molecular genetic features that provide diagnostic, prognostic, and predictive values [33, 34] , facilitating patient stratification, prognosis, and treatment response [35] . GBM is one of the most aggressive and difficult to treat human malignancies, due to the frequent dysfunctions of tumour suppressors or oncogenes and highly diffusive growth, which prevents tumour resection and contributes to rapid tumour recurrence [36] . GBMs show alterations in EGFR, PDGFRA, PTEN, TP53, NF1, and CDKN2A/B, TERT promoter mutations, and rarely IDH1/2 mutations (5%, mainly secondary GBMs that develop from lower grade tumours) [37, 38] . The golden standard of GBM treatment is surgery combined with chemo-and radiotherapy; however, it remains only palliative and the median survival time of adult patients with GBM is 14-15 months after diagnosis [39] .
Glioma cells secrete numerous chemokines, cytokines, and growth factors that promote infiltration of various cells, including a vast majority of immune cells such as microglia, peripheral macrophages, MDSCs, leukocytes, mostly CD4 + T cells, and Treg [40] [41] [42] [43] . These non-neoplas- tic cells create a specific niche within a tumour microenvironment, which plays an important role in glioma growth, metastasis, and response to treatment. Locally produced cytokines and chemokines and their crosstalk with components of the extracellular matrix re-educate infiltrating immune cells to acquire distinct functional properties, directing the immune system towards immunosuppressive responses. Like many other non-CNS malignant cancers, GBMs developed multiple strategies to inhibit host antitumour responses [44] . Several recent transcriptomic studies of GBM tissues have identified "immune and myeloid/ macrophage" gene expression signatures associated with GBM pathology, overall survival (OS), or response to treatment [45] [46] [47] . These data strongly support a link between a type of the immune response, accumulation of specific immune cell subsets, and glioma progression. Clinical studies showed extensive infiltration of gliomas with myeloid cells; the majority of them are microglia and peripheral macrophages, collectively termed glioma-associated microglia/macrophages (GAMs). Immunohistochemical studies using various markers demonstrated the higher abundance of GAMs in high-grade gliomas than in low-grade gliomas [48] [49] [50] [51] . Application of flow cytometry allowed for more detailed analyses of myeloid subpopulations. A flow cytometry phenotype for ramified microglia isolated from adult CNS was defined as CD45 ) in rat C6, 9L, and RG-2 glioma models, and demonstrated that microglia infiltration is dependent on the glioma cell line but does not correlate with the tumour size [54] . Microglia accounted for 13-34% of the tumour mass within the tumour periphery. Macrophages represented a smaller proportion of the infiltrating cells, accounting for 5-12% of cells, and this proportion was constant in different models [54] . In the transgenic RCAS-PDGFb tumour model in which RFP -/GFP + microglia and RFP + /GFP low macrophages/monocytes were isolated from tumours, flow cytometry studies demonstrated 14% microglia and 8.5% macrophages/monocytes in the RCAS-PDGFb gliomas, and a similar proportion of GAMs (16% microglia and 6.5% macrophages/monocytes) was observed in GL261 tumours [58] .
Immunohistochemical evaluation of functional markers and gene expression profiling of human GBM infiltrating CD11b + cells indicate immunosuppressive activation of GAMs and point to a lack of the classical "immune response" activation in GBMs [51, [58] [59] [60] . The studies using pharmacological or genetic ablation of CD11b + cells in experimental glioma models demonstrated that tumours do not grow and invade the brain parenchyma if GAMs are ablated or functionally paralysed [59, [61] [62] [63] [64] [65] [66] . In those studies the percentages of MDSCs and their functionality were not evaluated.
Myeloid-derived suppressor cells in gliomas
The numbers of MSDCs are frequently increased in blood, spleen, and tumour mass, and they correlate with cancer stage, metastasis, and chemotherapy response [18] . Information regarding their presence and roles in gliomas is scarce [4, 67] . Gielen et al. [4] reported increased percentages of both M-MDSCs and PMN-MDSCs in the blood of GBM patients when compared with healthy donors. The myeloid activation markers B7-1/CD80 and PD-L1 were not detected, and CD124, CD86, and CD40 were detected at similar levels on MDSCs in glioma patients and healthy donors. + effector memory T-cells (CD4 + T em ) within the tumours was detected. Tumour-derived CD4 + T em expressed high levels of PD-1 and was functionally exhausted. The expression of PD-L1 was also significantly upregulated on tumour-derived MDSCs [68] . The presented findings provide evidence for the accumulation of different MDSC subsets in GBM patients and indicate that PMN-MDSCs in peripheral blood and at the tumour site may participate in GBM-induced T-cell suppression. Accumulation of MDSCs in peripheral blood in GBM patients may induce T-cell immunosuppression, and increased plasma levels of Arginase 1 and G-CSF may contribute to MDSC suppressor function and its expansion [4] .
These results are corroborated by our studies, which show a large number of Arg1 + but not Iba1 + cells (GAMs) infiltrating experimental C6 gliomas in rats [66] . Flow cytometry studies of double-positive cells -CD11b Recent studies indicate that GAMs (in particular CD163 + infiltrating macrophages) within the glioma microenvironment produce Ccl2, a chemokine recruiting both Ccr2 + Ly-6C + Mo-MDSCs and Ccr4 + Treg. In murine gliomas, tumour-derived Ccl20 and osteoprotegerin induced Ccl2 production by GAMs. Gliomas developing in Ccl2-deficient mice displayed reduced Tregs and monocytic MDSCs infiltration [69] . Macrophage migration inhibitory factor (MIF), which was produced at high levels by glioma stem-like cells (CSCs), increased the expression of the arginase-1 in MDSCs in a receptor Cxcr2-dependent manner. Reduction of MIF conferred a survival advantage to tumour-bearing animals and increased the cytotoxic T cell response towards the tumour [70] . M-MDSCs of GBM patients have increased levels of intracellular S100A8/9 and serum levels compared with M-MDSCs in healthy controls. Glioma patients also have increased S100A8/9 serum levels, which correlates with increased Arginase activity in serum [71] . 
Antitumour immune responses in glioma microenvironment
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+ Treg was correlated with tumour resistance to radiation and chemotherapy, poor prognosis, and higher grade [43, 44] . Treg cells are known as suppressors of the adaptive immune response inhibiting the proliferation of effector T cells. Treg suppressive mechanism depends on the cell-cell interaction and is implicated in a host tolerance in tumour growth [55] . The tumour-infiltrating CD8 + T cells were phenotypically CD8 + CD25 -, suggesting that these cells were not activated. CD4 + T cells were more numerous than CD8 + T cells within glioma tissues, and the percentages of CD4 + and CD8 + cells increased with tumour grade [74, 75] . Anti-tumour immune responses mediated by T cells are suppressed by TGF-β and IL-10 secreted by glioma cells [44] . Moreover, glioma cells lack B7.1/2 (CD80/86), costimulatory and immune regulatory molecules, but constitutively express B7-H1 mRNA and protein. Glioma-related B7-H1 was identified as a strong inhibitor of CD4 + as well as CD8 + T-cell activation [75] . GBM infiltrating T-cells had decreased INF-γ production and increased PD-1 gene expression [68] . As well as directly blocking effective activation of naive T cells, glioma cells promote accumulation of Treg and MDSCs that mediate inhibition of T cells and NK cells.
Immunotherapeutic approaches for GBM, such as immune checkpoint blockade and anti-tumour vaccines, are actively tested in preclinical models and the first combinations of immunotherapies with standard therapies are being translated to clinical trials. Phase I clinical trial studying the effects of anti-PD-1 and anti-CTLA-4 combination therapy for recurrent GBM (NCT02017717), and a number of studies of DC vaccines in recurrent and newly diagnosed GBM are in progress (NCT02010606, NCT02149225, NCT02049489, NCT01808820, NCT02078648), and an entire medical community awaits results. Further understanding the biology of MDSCs and conditions for their polarisation in the tumour microenvironment and peripheral blood may be crucial for the development of new therapeutic strategies.
